J&J Submits Paliperidone ER
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson submitted an NDA Nov. 29 for its Risperdal follow-on paliperidone extended-release, the firm said Nov. 30
You may also be interested in...
Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy
While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.
Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy
While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.
J&J Paliperidone ER To Go Before Advisory Panel Weeks Before User Fee Date
The firm could have an eight-month lead over AstraZeneca’s once-a-day antidepressant.